The Resonance Health share price was edging higher today before the company announced that it would be entering a trading halt.
The post Resonance Health (ASX:RHT) announces its share price is in trading halt appeared first on The Motley Fool Australia. –
The Resonance Health Limited (ASX: RHT) share price has been placed in a trading halt. This comes after an announcement by the company this afternoon. Prior to the halt, the Resonance Health share price was trading narrowly higher. Rising to 19.5 cents, up by 2.63%.
The Resonance Health share price has been a poor performer so far this year, shedding 15%. Let’s take a closer look at what this means for the company.
What Resonance Health does
Resonance Health is an Australian healthcare company. It is involved in the development and delivery of non-invasive medical imaging software and services. Resonance Health’s products are used by clinicians in the diagnosis and management of human diseases. Its products are also used by pharmaceutical companies in their clinical trials.
The Company’s flagship product is its HepaFat-AI technology. This gained FDA approval earlier this year. The FDA approval which paves the way for commercialisation of the technology sent its shares 80% higher on the day.
HepaFat-AI results can be used to monitor liver fat content in patients undergoing weight loss management. Additionally, it can aid in the assessment and screening of living donors for liver transplants.
This afternoon, the Resonance Health share price is at a standstill. This is due to the company announcing that it would be entering a trading halt. Shares in the company will not begin trading until February 19 or when the announcement is made. Whichever is earliest.
The small cap share requested a trading halt pending the announcement in relation to regulatory approval that affects the company’s share price. With the trading halt now in effect, shareholders will be eagerly awaiting the release of any news.
About the Resonance share price
It has been a volatile 6 months for Resonance Health. Consequently, its share price has jumped between 13.5 and 32.5 cents. Nonetheless, shares in the company are currently trading at a price of 19.5 cents. This is despite having dropped lower since the start of the year.
Resonance Health currently boasts a market capitalisation of $87 million.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Why the Openpay (ASX:OPY) share price is surging higher today
- The Peninsula Energy (ASX: PEN) share price continues to fly
- Why the McPherson’s (ASX:MCP) share price was crushed today
- Pilbara Minerals (ASX:PLS) share price jumps 6% on broker upgrades
- What’s going on with the Cirralto (ASX:CRO) share price?
Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Resonance Health Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.